HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant

BACKGROUND: Subsets of high grade endometrial cancer (EnCa) over-express HER2 (ERBB2), yet clinical trials have failed to demonstrate any anti-tumor activity utilizing trastuzumab, an approved platform for HER2 positive breast cancer (BrCa). A truncated p95HER2 variant lacking the trastuzumab bindin...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Gynecol Oncol
Glavni autori: Growdon, Whitfield B., Groeneweg, Jolijn, Byron, Virginia, DiGloria, Celeste, Borger, Darrell R., Tambouret, Rosemary, Foster, Rosemary, Chenna, Ahmed, Sperinde, Jeff, Winslow, John, Rueda, Bo R.
Format: Artigo
Jezik:Inglês
Izdano: 2015
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4380649/
https://ncbi.nlm.nih.gov/pubmed/25602714
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2015.01.533
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items